Time to read
2 minutes
Read so far

Precision editing of gut bacteria reduces cancer in mice

Fri, 08/02/2019 - 13:04
Posted in:

UT Southwestern researchers have shown that precision editing of the bacterial populations in the gut reduces inflammation-associated colorectal cancer in mice. It is hoped the study could lay the groundwork for novel cancer prevention strategies for individuals with chronic intestinal inflammation. The study, ‘Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer’, was published in The Journal of Experimental Medicine.

Inflammatory bowel disease (IBD) affects more than 1.6 million people in the US, about equally divided between those with ulcerative colitis and Crohn's disease, said co-corresponding author Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of UT Southwestern's Division of Digestive and Liver Diseases.

People living with IBD have a higher risk of developing colon cancer, which can be a source of significant health consequences for these patients, he said. The World Health Organization lists colorectal cancer as the third most-common cancer worldwide and the second highest cause of malignancy-related death.

IBD increases the risk of colorectal cancer by three- to sevenfold. Because of that association, patients with persistent bowel inflammation should a colonoscopy, three to ten times more often than healthy people who have no family history of such cancer: every one to three years vs. every he, he explained.

"The most significant finding in this study is that manipulating the intestinal microbiome is sufficient to affect the development of tumours,” he added. “One could envision a time in which medications that change the behaviour and composition of the bacteria that live in the gut will be part of the treatment for IBD.”

In addition to colorectal cancer, long-standing IBD is associated with imbalances in the bacterial species that line the gut, explained co-corresponding author Dr Sebastian Winter, Assistant Professor of Microbiology and Immunology and a W W Caruth, Jr Scholar in Biomedical Research. The study's first author is Dr. Wenhan Zhu, a postdoctoral researcher in the Winter laboratory.

"Our intestinal tract is teeming with microbes, many of which are beneficial and contribute to our overall health,” said Winter. “Yet, under certain conditions, the normal function of these microbial communities can be disturbed. An overabundance of certain microbes is associated with increased risk for the development of diseases, including certain cancers.”

The strategy used in the study targets metabolic pathways that are only active during intestinal inflammation and only in some forms of bacteria, providing an Achilles' heel for reducing their abundance. The current study builds on work the researchers published last year in Nature that found the approach prevented or reduced inflammation in a mouse model of colitis, while having no obvious effect on healthy control animals with balanced bacterial populations in their guts.

(Left to right) Drs Sebastian Winter, Ezra Burstein and Wenhan Zhu (Credit: UTSW)
(Left to right) Drs Sebastian Winter, Ezra Burstein and Wenhan Zhu (Credit: UTSW)

"For example, most Escherichia coli bacteria are harmless and protect the human gut from other intestinal pathogens such as Salmonella, a common cause of food poisoning. However, a subset of E. coli bacteria produce a toxin that induces DNA damage and can cause colon cancer in research animals. We developed a simple approach - giving a water-soluble tungsten salt to mice genetically predisposed to develop inflammation - to change the way potentially harmful E. coli bacteria generate energy for growth. Restricting the growth of these bacteria decreased intestinal inflammation and reduced the incidence of tumours in two models of colorectal cancer," Winter added. “Tungsten is a heavy metal and should not be used by anyone due to its toxicity. As with our 2018 paper, this is a proof-of-concept study that will guide us in developing future drugs with similar activity and less toxicity."

Precision editing of the gut microbiome is a shift in strategy from current clinical treatments that target reducing inflammation in the patient during IBD flare-ups or using broad-spectrum antibiotics that kill both good and bad bacteria in order to reduce the risk of cancer, the researchers said.

"Here, we present evidence that targeting the gut microbiota can be sufficient to affect tumour formation in a significant and meaningful way," Winter concluded.